<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase I: Development and Commercialization of the SafeLight Family of Antimicrobial Materials for Combatting the COVID-19 Pandemic and Hospital Acquired Infections</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>06/01/2020</AwardEffectiveDate>
<AwardExpirationDate>12/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>225000.00</AwardTotalIntnAmount>
<AwardAmount>225000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Erik Pierstorff</SignBlockName>
<PO_EMAI>epiersto@nsf.gov</PO_EMAI>
<PO_PHON>7032922165</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact of this Small Business Technology Transfer (STTR) Phase I project is the development of new antimicrobial materials to reduce the spread of harmful bacteria and viruses in a variety of settings, particularly for self-disinfecting personal protection equipment against SARS-CoV-2 to combat the COVID-19 pandemic. While primarily intended for use in hospitals, these antimicrobial materials can also impact bio-defense; military facilities; food processing, packaging, and service industries; wastewater treatment facilities; daycare and long-term care facilities; and even personal households. Beyond the current pandemic, this technology can address hospital-acquired infections, which add an estimated $30-45 billion to health care costs every year; and the food service industry, where norovirus foodborne infections alone account for an economic loss of about $5.8 B annually in the United States.  The proposed technology offers significant benefit for the current COVID-19 challenge and beyond. &lt;br/&gt;&lt;br/&gt;The proposed project will develop light-activated surface-disinfecting materials based on photodynamic inactivation that generates singlet oxygen – a highly reactive yet environmentally benign species – to cause non-specific damage to microbes, rendering them inactive. The technical challenges are: 1) the development of chemical species capable of producing singlet oxygen upon exposure to light, but stable at the high temperatures of manufacturing processes, for which we will start with a known class of compounds; 2) the development of a method for the production and embedding of the newly-developed photoreactive compounds within relevant materials, particularly for the manufacture of personal protection equipment; and 3) evaluation of process efficacy for virucidal (against coronaviruses), antibacterial, antimycotic and sporicidal use.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>05/29/2020</MinAmdLetterDate>
<MaxAmdLetterDate>06/12/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2014753</AwardID>
<Investigator>
<FirstName>Reza</FirstName>
<LastName>Ghiladi</LastName>
<PI_MID_INIT>A</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Reza A Ghiladi</PI_FULL_NAME>
<EmailAddress>reza_ghiladi@ncsu.edu</EmailAddress>
<PI_PHON>9195152444</PI_PHON>
<NSF_ID>000497047</NSF_ID>
<StartDate>05/29/2020</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Mahmut</FirstName>
<LastName>Dirican</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Mahmut Dirican</PI_FULL_NAME>
<EmailAddress>mdirican34@gmail.com</EmailAddress>
<PI_PHON>9842558105</PI_PHON>
<NSF_ID>000793312</NSF_ID>
<StartDate>05/29/2020</StartDate>
<EndDate>06/12/2020</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Robert</FirstName>
<LastName>Sheehan</LastName>
<PI_MID_INIT>J</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Robert J Sheehan</PI_FULL_NAME>
<EmailAddress>rsheehan300@gmail.com</EmailAddress>
<PI_PHON>8598169706</PI_PHON>
<NSF_ID>000830522</NSF_ID>
<StartDate>06/12/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>PHOTOCIDE PROTECTION, INC.</Name>
<CityName>RALEIGH</CityName>
<CountyName/>
<ZipCode>276950001</ZipCode>
<PhoneNumber>9196241744</PhoneNumber>
<StreetAddress>4512 THOMAS HALL</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>North Carolina</StateName>
<StateCode>NC</StateCode>
<CONGRESSDISTRICT/>
<CONGRESS_DISTRICT_ORG/>
<ORG_DUNS_NUM>117057795</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>PHOTOCIDE PROTECTION, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[North Carolina State University]]></Name>
<CityName>Raleigh</CityName>
<CountyName/>
<StateCode>NC</StateCode>
<ZipCode>276957615</ZipCode>
<StreetAddress><![CDATA[2620 Yarbrough Dr]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>North Carolina</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF/>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~225000</FUND_OBLG>
</Award>
</rootTag>
